The blood coagulation system as a molecular machine

BioEssays

Volumn 25, Issue 12, 2003, Pages 1220-1228

  Spronk, Henri M H ^a   Govers Riemslag, José W P ^a   Ten Cate, Hugo ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; CALCIUM ION; ENZYME; FIBRIN; GLYCOPROTEIN; PHOSPHOLIPID; PROTEIN;

ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD CLOTTING; DISSEMINATED INTRAVASCULAR CLOTTING; HEMOSTASIS; IMMUNITY; INFLAMMATION; MICROVASCULATURE; MOLECULAR BIOLOGY; MOLECULAR MACHINE; REVIEW; THROMBOSIS;

ANTICOAGULANTS; BLOOD COAGULATION; HEMOSTASIS; HUMANS; KINETICS; MODELS, BIOLOGICAL; PHENOTYPE; PHOSPHOLIPIDS; PROTHROMBIN; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 0344630172     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.10360     Document Type: Review

References (83)

1. Lind S, Marks P, Ewenstein B. Blood: Principles and practice of hematology. Philadelphia, PA: Lippincott Williams & Wilkins. 2003
2. Hoffman M, Monroe DM, 3rd. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-965.
3. Dahlback B. Blood coagulation. Lancet 2000;355:1627-1632.
4. Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Srivastava A. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160-174.
5. Versteeg HH, Peppelenbosch MP, Spek CA. The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signalling? Thromb Haemost 2001;86:1353-1359.
6. Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000;1477:349-360.
7. Sidelmann JJ, Gram J, Jespersen J, Kluft C. Fibrin clot formation and lysis: basic mechanisms. Semin Thromb Hemost 2000;26:605-618.
8. Malpighi M. De polypo cordis. Dissertatio. Opera omnia lugundi batavorum. 1687;Part 2:311-319.
9. Hammarsten O. Weitere Beiträge zur Kenntnis der Fibrinbildung. Zeitrschr Physiol Chem 1899;28:98-114.
10. Buchanan A. Contributions to the physiology and pathology of the animal fluids. London Med Gaz 1836;18:50-54;90-93.
11. Buchanan A. On the coagulation of blood and other fibriniferous liquids. Proc R Phul Soc Glasgow 1845;2:16-22.
12. Pekelharing C. Untersuchung über das Fibrinferment. Internat Beitr Zschr Wissensch Med (Festschr Rudolf Virchow) 1891;1:433-456.
13. Schmidt A. Zur Blutlehre. Leipzig: Vogel. 1892
14. Arthus M, Pagès C. Nouvelle theorie chimique de la coagulation du sang. Arch Physiol Norm Pathol 1890;5:739-749.
15. Bizzozero J. Ueber einen neuen formbestandtheil des blutes und dessen rolle bei der thrombose und der blutgerinnung. Virchows Arc Pathol Anat Physiol Klin Med 1882;90:261-332.
16. Hayem G. Sur le mécanisme de l'arrêt des hémorrhagies. C R Acad Sci 1882;95:18-21.
17. Eagle H. Studies on blood coagulation, IV: the nature of the clotting deficiency in hemophilia. J Gen Physiol 1935;18:813-819.
18. Quick A, Stanly-Brown M, Bancroft F. A study of the coagulation defect of hemophilia and in jaundice. Am J Med Sci 1935;190:501-511.
19. Owren P. The coagulation of blood: investigations on a new clotting factor. Acta Med Scand 1947;Supl 194:
20. Alexander B, Goldstein R, Landwehr G, Cook C. Congenital SPCA deficiency; a hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum reactions. J Clin Invest 1951;30:17-22.
21. Patek A, Taylor F. Hemophilia. II. Some properties of a substance obtained from normal plasma effective in accelerating the clotting of hemophilic blood. J Clin Invest 1937;16:113.
22. Pavlovsky A. Contribution to the Pathogenesis of Hemophilia. Blood 1947;2:185.
23. Duckert F, Flückiger P, Matter M, Koller F. Clotting factor X. Physiologic and physiochemical properties. Proc Soc exp Biol Med 1955;90:17-22.
24. Rosenthal R, Dreskin O, Rosenthal N. New hemophilia-like disease caused by defiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med 1953;82:171-174.
25. Ratnoff O, Colopy J. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955;34:602-613.
26. Wilcox JN, Noguchi S, Casanova J. Extrahepatic synthesis of factor VII in human atherosclerotic vessels. Arterioscler Thromb Vasc Biol 2003;23:136-141.
27. Macfarlane R. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964;202:498-499.
28. Davie E, Ratnoff O. Waterfall sequence for intrinsic blood clotting. Science 1964;145:1310-1312.
29. Colman R, Marder V, Salzman E, Hirsch J. Overview of hemostasis. In: Colman R, Hirsch J, Marder V, Salzman E, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practise. Philadelphia: JB Lippincott. 1987. p 3-17.
30. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol 2001;115:3-12.
31. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977;74:5260-5264.
32. Bouma BN, Mosnier LO, Meijers JC, Griffin JH. Factor XI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation. Thromb Haemost 1999;82:1703-1708.
33. Gailani D, Broze GJ, Jr. Factor XI activation by thrombin and factor XIa. Semin Thromb Hemost 1993;19:396-404.
34. von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995;86:3035-3042.
35. ten Cate H, Biemond BJ, Levi M, Wuillemin WA, Bauer KA, Barzegar S, Buller HR, Hack CE, ten Cate JW, Rosenberg RD. Factor XIa induced activation of the intrinsic cascade in vivo. Thromb Haemost 1996;75:445-449.
36. Roberts HR, Monroe DM, Oliver JA, Chang JY, Hoffman M. Newer concepts of blood coagulation. Haemophilia 1998;4:331-334.
37. Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost 1996;75:767-771.
38. Minnema MC, Peters RJ, de Winter R, Lubbers YP, Barzegar S, Bauer KA, Rosenberg RD, Hack CE, ten Cate H. Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol 2000;20:2489-2493.
39. Berliner JI, Rybicki AC, Kaplan RC, Monrad ES, Freeman R, Billett HH. Elevated levels of Factor XI are associated with cardiovascular disease in women. Thromb Res 2002;107:55-60.
40. Levi M, Hack CE, de Boer JP, Brandjes DP, Buller HR, ten Cate JW. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo. J Clin Invest 1991;88:1155-1160.
41. Schousboe I. Binding of activated Factor XII to endothelial cells affects its inactivation by the C1-esterase inhibitor. Eur J Biochem 2003;270:111-118.
42. Schousboe I. Rapid and cooperative binding of factor XII to human umbilical vein endothelial cells. Eur J Biochem 2001;268:3958-3963.
43. Shariat-Madar Z, Mahdi F, Schmaier AH. Assembly and activation of the plasma kallikrein/kinin system: a new interpretation. Int Immunopharmacol 2002;2:1841-1849.
44. van Rijn JL, Govers-Riemslag JW, Zwaal RF, Rosing J. Kinetic studies of prothrombin activation: effect of factor Va and phospholipids on the formation of the enzyme-substrate complex. Biochemistry 1984;23:4557-4564.
45. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003;23:17-25.
46. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993;70:617-624.
47. Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Beguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000;83:589-591.
48. Wolberg A, Monroe D, Roberts H, Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood 2003; In Press.
49. Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation. Thromb Haemost 1999;82:695-705.
50. Bauer K, Zwicker J. Blood: Principles and practice of hematology. Philadelphia, PA: Lippincott Williams & Wilkins. 2003
51. Esmon CT. Coagulation and inflammation. J Endotoxin Res 2003;9:192-198.
52. Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003;9:338-342.
53. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Hameorrh 1965;13:516.
54. Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003;101:4387-4392.
55. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000;95:1517-1532.
56. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-1008.
57. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
58. Rosing J, Tans G, Nicolaes GA, Thomassen MC, van Oerle R, van der Ploeg PM, Heiinen P, Hamulyak K, Hemker HC. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997;97:233-238.
59. Nicolaes GA, Dahlback B. Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol 2002;22:530-538.
60. Govers-Riemslag JW, Castoldi E, Nicolaes GA, Tans G, Rosing J. Reduced factor V concentration and altered FV1/FV2 ratio do not fully explain R2-associated APC-resistance. Thromb Haemost 2002;88:444-449.
61. ten Cate H, Aird W. Lessons from venous thrombosis and disseminated intravascular coagulation: A synthesis of pathophysiological mechanisms of prothrombotic states. In: ten Caten H, Levi M, editors. Molecular mechanisms of disseminated intravascular coagulation. Texas: Landes Bioscience publishers. 2003.
62. Aird W. Hemostasis and irreducible complexity. J Thromb Haemost 2003;1:227-230.
63. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999;340:1555-1564.
64. Corti R, Farkouh ME, Badimon JJ. The vulnerable plaque and acute coronary syndromes. Am J Med 2002;113:668-680.
65. Khrenov AV, Ananyeva NM, Griffin JH, Saenko EL. Coagulation pathways in atherothrombosis. Trends Cardiovasc Med 2002;12:317-324.
66. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 2001;104:3063-3068.
67. Rosendaal F. Clotting and myocardial infarction: a cycle of insights. J Thromb Haemost 2003;1:640-642.
68. Levi M, ten Cate H, van der Poll T. Endothelium: interface between coagulation and inflammation. Crit Care Med 2002;30:S220-S224.
69. Taylor FB, Jr. Staging of the pathophysiologic responses of the primate microvasculature to Escherichia coli and endotoxin: examination of the elements of the compensated response and their links to the corresponding uncompensated lethal variants. Crit Care Med 2001;29:S78-S89.
70. Krem MM, Cera ED. Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem Sci 2002;27:67-74.
71. Iwanaga S, Kawabata S, Muta T. New types of clotting factors and defense molecules found in horseshoe crab hemolymph: their structures and functions. J Biochem (Tokyo) 1998;123:1-15.
72. Kairies N, Beisel HG, Fuentes-Prior P, Tsuda R, Muta T, Iwanaga S, Bode W, Huber R, Kawabata S. The 2.0-A crystal structure of tachylectin 5A provides evidence for the common origin of the innate immunity and the blood coagulation systems. Proc Natl Acad Sci USA 2001;98:13519-13524.
73. Sommeijer D, Reitsma P. Genetic risk factors for disseminated intrevascular coagulation. In: ten Cate H, Levi M, editors. Molecular mechanisms of disseminated intravascular coagulation. Texas: Landes Bioscience publishers. 2003. In Press.
74. Hermans PW, Hibberd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, Levin M. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999;354:556-560.
75. Westendorp RG, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999;354:561-563.
76. Taylor FB, Jr., Chang AC, Peer GT, Mather T, Blick K, Catlett R, Lockhart MS, Esmon CT. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 1991;78:364-368.
77. Bernard GR, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
78. Erlich JH, et al. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol 2000;157:1849-1862.
79. Luther T, Dittert DD, Kotzsch M, Erlich J, Albrecht S, Mackman N, Muller M. Functional implications of tissue factor localization to cell-cell contacts in myocardium. J Pathol 2000;192:121-130.
80. Cunningham MA, Rondeau E, Chen X, Coughlin SR, Holdsworth SR, Tipping PG. Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med 2000;191:455-462.
81. Schoenecker JG, Johnson RK, Lesher AP, Day JD, Love SD, Hoffman MR, Ortel TL, Parker W, Lawson JH. Exposure of mice to topical bovine thrombin induces systemic autoimmunity. Am J Pathol 2001;159:1957-1969.
82. Ruf W, Fischer EG, Huang HY, Miyagi Y, Ott I, Riewald M, Mueller BM. Diverse functions of protease receptor tissue factor in inflammation and metastasis. Immunol Res 2000;21:289-292.
83. Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980;255:274-283.